|Issue 1,672: January 11, 2023
Immunize.org Pages and Handouts
Vaccine Information Statements
Medicare Part D eliminates recipients’ out-of-pocket costs for all ACIP-recommended vaccines starting January 1, 2023
The Inflation Reduction Act (IRA) eliminated out-of-pocket costs as of January 1, 2023, for Medicare Part D beneficiaries who receive vaccines recommended for adults by the Advisory Committee on Immunization Practices (ACIP). For the first time, people with Medicare’s prescription drug coverage will pay no deductible and will not be responsible for any cost-sharing for ACIP-recommended vaccines, including shingles vaccine, Tdap, and travel vaccines.
Back to top
Immunize.org published a comprehensive update of the clinical answers in its popular Ask the Experts: COVID-19 web page on December 23. This extensive set of clinical questions and answers addresses CDC COVID-19 recommendations and clinical considerations and connects readers with CDC resources. Updates incorporate policy changes made since September 8, such as booster dose recommendations for children who begin the series as early as age 6 months and the limited use of Novavax COVID-19 Vaccine as a first booster dose for some adults.
Newly updated “65+ Flu Defense” website offers resources for healthcare professionals serving older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense website.
Check out the updated 65+ Flu Defense website at www.influenza-defense.org to assist your ongoing efforts in protecting this vulnerable population.
Now is the best time to vaccinate anyone not yet protected from influenza this season. CDC’s Weekly U.S. Influenza Surveillance Report, FluView, provides a valuable snapshot of influenza activity state-by-state.
January is Cervical Health Awareness Month, a great time to share the importance of human papillomavirus (HPV) vaccine. Almost all cervical cancer cases (99%) are linked to infection with high-risk HPV strains, an extremely common virus transmitted through intimate contact.
In this week's Spotlight, we summarize Immunize.org companion websites.
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Immunize.org Pages and Handouts
Recap: These updated Immunize.org educational materials for clinicians were released during November and December
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
Vaccine Information Statements
Immunize.org continues to expand its translations of new and updated Vaccine Information Statements for DTaP, hepatitis A, hepatitis B, Hib, and smallpox/mpox vaccines. Be sure you are up to date!
Thanks to CDC support Immunize.org substantially expanded its repository of Vaccination Information Statement (VIS) translations. In November and December, Immunize.org posted new and updated VIS translations for DTaP, Hib, hepatitis A, hepatitis B, and smallpox/mpox vaccines.
Haemophilus influenzae type b (Hib) VIS (view in English)
Hepatitis A VIS (view in English)
Hepatitis B VIS (view in English)
Smallpox/Monkeypox (JYNNEOS™) VIS (view in English)
Check the version dates of your office copies of newly updated translations. Translations of previous VIS versions should be discarded now that translations of the current versions are available.Related Links
Recap: A record number of Vaccine Information Statement translations were released during November and December
IZ Express regularly provides readers with information about Vaccine Information Statements (VISs) and translations of VISs. In November, with support from CDC, Immunize.org began working with partners to significantly increase the number of VIS translations available. If your facility works with patients whose primary language is not English, please review and use these translations when needed.
Reminder: Immunize.org’s new webinar, “Improving the Vaccination Experience: Accessible Vaccination for Neurodiverse People at Any Age,” available for on-demand viewing
On December 13, Immunize.org and experts from the Autism Society hosted a 1-hour webinar, Improving the Vaccination Experience: Accessible Vaccination for Neurodiverse People at Any Age. In this webinar, participants learned more about the Autism Society’s practical tips to improve vaccine confidence by employing strategies to reduce stress when vaccinating neurodiverse patients.
Help Immunize.org reach more vaccinators through your social media networks. Follow us and share our posts featuring Ask the Experts questions and our clinical resources on Facebook, Twitter, and Instagram!
Immunize.org launched a new social media program to highlight our educational resources for a new audience of vaccinators. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Our Instagram account is new and we need your support to build our following!
Each additional follower extends the reach of our work to help healthcare professionals deliver quality vaccination services to people of all ages.
“Racial and Ethnic Differences in COVID-19 Vaccination Coverage among Children and Adolescents Aged 5–17 Years and Parental Intent to Vaccinate Their Children—National Immunization Survey–Child COVID Module, United States, December 2020–September 2022” published in MMWR
CDC published Racial and Ethnic Differences in COVID-19 Vaccination Coverage among Children and Adolescents Aged 5–17 Years and Parental Intent to Vaccinate Their Children—National Immunization Survey–Child COVID Module, United States, December 2020–September 2022 on January 6 in MMWR. A portion of the summary appears below.
Some racial and ethnic groups are at increased risk for COVID-19–associated morbidity and mortality because of systemic and structural inequities. Vaccination is effective in preventing severe COVID-19–related outcomes. . . .
Among children and adolescents aged 5–17 years, ≥1-dose COVID-19 vaccination coverage was low overall, but highest among Asian and Hispanic or Latino children and adolescents. Parental intent to vaccinate their child varied by the child’s age, race, and ethnicity. Parents of unvaccinated children and adolescents reported low confidence in vaccine safety, and a low percentage reported receipt of a provider vaccination recommendation. . . .
To increase overall coverage and address disparities in child and adolescent COVID-19 vaccination coverage, providers and trusted messengers should provide culturally relevant information and vaccine recommendations.
Back to top
“Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations among Immunocompetent Adults—VISION Network, Nine States, September–November 2022” published in MMWR
CDC published Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations among Immunocompetent Adults—VISION Network, Nine States, September–November 2022 on December 30 in MMWR. A portion of the summary appears below.
Bivalent mRNA COVID-19 booster doses containing an Omicron BA.4/BA.5 sublineage component were recommended on September 1, 2022. . . .
Bivalent booster doses provided additional protection against COVID-19–associated emergency department/urgent care encounters and hospitalizations in persons who previously received 2, 3, or 4 monovalent vaccine doses. Because of waning of monovalent vaccine-conferred immunity, relative effectiveness of bivalent vaccines was higher with increased time since the previous monovalent dose. . . .
“Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization among Immunocompetent Adults Aged ≥65 Years—IVY Network, 18 States, September 8–November 30, 2022” published in MMWR
CDC published Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization among Immunocompetent Adults Aged ≥65 Years—IVY Network, 18 States, September 8–November 30, 2022 on December 30 in MMWR. A portion of the summary appears below.
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; . . .
Among immunocompetent adults aged ≥65 years hospitalized in the multistate IVY Network, a bivalent booster dose provided 73% additional protection against COVID-19 hospitalization compared with past monovalent mRNA vaccination only. . . .
To maximize protection against severe COVID-19 this winter season, all eligible persons, especially adults aged ≥65 years, should receive a bivalent booster dose and consider additional prevention strategies, including masking in indoor public spaces.
“Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons—29 U.S. Jurisdictions, May 22–September 3, 2022” published in MMWR
CDC published Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons—29 U.S. Jurisdictions, May 22–September 3, 2022 on December 30 in MMWR. A portion of the summary appears below.
Analysis of mpox infections among unvaccinated persons and those who had received 1 JYNNEOS vaccine dose ≥14 days before illness onset found that the odds of fever, headache, malaise, myalgia, and chills were significantly lower among vaccinated patients than among unvaccinated patients. Overall, 2% of vaccinated persons with mpox and 8% of unvaccinated patients were hospitalized. . . .
One dose of JYNNEOS vaccine might attenuate the severity of illness and reduce hospitalization in persons who become infected after vaccination; however, to optimize protection, all eligible persons are recommended to complete the 2-dose vaccination series.
For more upcoming events, visit our Calendar of Events.